In a research experiment, Tumas et al. (2023) modified Escherichia coli Nissle 1917 (EcN) to continuously produce interleukin-2 (IL-2) for the treatment of inflammatory bowel disease following oral delivery; the engineered strain reestablished immune equilibrium and improved disease symptoms in animal models [24]. The gene discussed is IL2; the disease is inflammatory bowel disease.